No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Fiche publication
Date publication
août 2016
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Lien Pubmed
Résumé
We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the ovarian reserve. Here, we report the final analysis of the cohort after 5 years of follow up.
Mots clés
Adult, Female, Fertility, drug effects, Fertility Preservation, methods, Gonadotropin-Releasing Hormone, agonists, Humans, Lymphoma, drug therapy, Middle Aged, Norethindrone, therapeutic use, Ovary, drug effects, Primary Ovarian Insufficiency, prevention & control, Prospective Studies, Triptorelin Pamoate, administration & dosage
Référence
J. Clin. Oncol.. 2016 08 1;34(22):2568-74